

OFFICE OF THE SECRETARY OF STATE

LAVONNE GRIFFIN-VALADE
SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE
AND TRIBAL LIAISON



ARCHIVES DIVISION

STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

TEMPORARY ADMINISTRATIVE ORDER
INCLUDING STATEMENT OF NEED & JUSTIFICATION

BP 66-2024

CHAPTER 855

BOARD OF PHARMACY

FILED

12/17/2024 2:09 PM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Temporarily amends Contraception, Coronavirus 19, Hepatitis B, Meningococcal, Pneumococcal, RSV protocols; Repeals VVC protocol

EFFECTIVE DATE: 12/17/2024 THROUGH 06/14/2025

AGENCY APPROVED DATE: 12/12/2024

CONTACT: Rachel Melvin

971-673-0001

pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150

Portland, OR 97232

Filed By:

Rachel Melvin

Rules Coordinator

NEED FOR THE RULE(S):

Temporarily adopts revised protocol for Contraception and revises vaccine protocols for Coronavirus 19, Hepatitis B containing vaccines, Meningococcal containing vaccines, Pneumococcal, and Respiratory Syncytial Virus to align with the most current Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations. Repeals the Vulvovaginal Candidiasis protocol.

JUSTIFICATION OF TEMPORARY FILING:

Failure to amend vaccine protocols in OAR 855-115-0345 to align with CDC ACIP recommendations may result in compromised patient access and care, posing a significant risk to public health by leaving individuals vulnerable to preventable diseases and potentially overwhelming other healthcare providers.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE:

Protocol Compendium:

Conditions: Vulvovaginal Candidiasis (VVC) https://www.oregon.gov/pharmacy/Documents/Cg-VVC_Protocol_v.62021_REPEAL.pdf

Preventative Care: Contraception https://www.oregon.gov/pharmacy/Documents/Ca-PrevCare_Contraception_v.12.2024.pdf

Vaccines:

Coronavirus 19 https://www.oregon.gov/pharmacy/Documents/Cb-PrevCare_IMZ_Coronavirus_19_v.12.17.2024.pdf

Hepatitis B containing vaccines https://www.oregon.gov/pharmacy/Documents/Cc-PrevCare_IMZ_Hepatitis_B_v.12.2024.pdf

*FDA announcement re: PreHevbrio® <https://www.fda.gov/vaccines-blood-biologics/prehevbrio>

Meningococcal containing vaccines https://www.oregon.gov/pharmacy/Documents/Cd-PrevCare_Meningococcal_v.12.2024.pdf

Pneumococcal https://www.oregon.gov/pharmacy/Documents/Ce-PrevCare_IMZ_Pneumococcal_v.12.17.2024.pdf

AMEND: 855-115-0345

RULE SUMMARY: Temporarily adopts revisions to the current Contraception protocol, proposes to temporarily adopt revised vaccine protocols for Coronavirus 19, Hepatitis B containing vaccines, Meningococcal containing vaccines, Pneumococcal, and Respiratory Syncytial Virus to align with the most current Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations. Per the FDA, PreHevbrio® has been voluntarily withdrawn from the market by the company, VBI Vaccines Inc., due to the bankruptcy of the company and the termination of its operations. Repeals the Vulvovaginal Candidiasis protocol as suggested by the Public Health & Pharmacy Formulary Advisory Committee.

CHANGES TO RULE:

855-115-0345

Services: Prescribing - Protocol Compendium

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices listed in the following compendium, pursuant to a statewide drug therapy management protocol. ¶

(1) Continuation of therapy including emergency refills of insulin and early refills of opioid use disorder medications (v. 08/2024)¶

(2) Conditions¶

(a) Cough and cold symptom management¶

(A) Benzonatate (v. 06/2021);¶

(B) Short-acting beta agonists (v. 06/2021);¶

(C) Intranasal corticosteroids (v. 06/2021);¶

~~(b) Vulvovaginal candidiasis (VVC) (v. 06/2021);¶~~

~~(c) COVID-19 Antigen Self-Test (v. 12/2021);¶~~

~~(d) SARS-CoV-2 Antiviral (v. 08/2024)¶~~

(3) Preventative care¶

(a) Emergency Contraception (v. 06/2021);¶

(b) Male and female condoms (v. 06/2021);¶

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024);¶

(d) Travel Medications (v. 06/2024);¶

(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);¶

(f) HIV Pre-exposure Prophylaxis (PrEP) (v.06/2023); ¶

(g) Contraception (v. ~~06/12/2023~~);¶

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);¶

(i) Short-acting Opioid Antagonists (v. 06/2024); and¶

(j) Vaccines:¶

(A) Standard Protocol for All Vaccines: Cover Page & Assessment and Treatment Care Pathway (v. 06/2024); ¶

(B) Standard Protocol for All Vaccines: Managing Adverse Reactions (v. 06/2024); ¶

(C) Cholera (v. 02/2024); ¶

(D) Coronavirus 2019 (v. 12/17/2024); ¶

(E) Haemophilus Influenza type b (v. 06/2024);¶

(F) Hepatitis A containing vaccines (v. 02/2024); ¶

(G) Hepatitis B containing vaccines (v. ~~01/12/2024~~); ¶

(H) Human Papillomavirus (v. 02/2024); ¶

(I) Influenza - Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 2024-2025 (v. 12/2024); ¶

(J) Influenza - Live Attenuated Influenza Vaccine 2024-2025 (v. 12/2024); ¶

(K) Japanese Encephalitis (v. 06/2024); ¶

(L) Meningococcal containing vaccines (v. ~~06/12/2024~~); ¶

(M) Measles Mumps & Rubella containing vaccines (v. 02/2024); ¶

(N) Pneumococcal (v. ~~06/12/2024~~); ¶

(O) Polio (v. 06/2024);¶

- (P) Rabies (v. 02/2024); ¶
- (Q) Respiratory Syncytial Virus (v. 12/17/2024); ¶
- (R) Tetanus Diphtheria containing vaccines (v. 06/2024); ¶
- (S) Typhoid (v. 02/2024); ¶
- (T) Varicella containing vaccines (v. 02/2024); ¶
- (U) Yellow fever (v. 06/2024); and ¶
- (V) Zoster (v. 02/2024). ¶

[Publications: Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205, 2024 HB 4002, 2024 SB 1506

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, 2024 HB 4002, 2024 SB 1506